TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Jade Biosciences ( (JBIO) ) is now available.
On June 26, 2025, Jade Biosciences entered into a master services agreement with Patheon Biologics LLC for the development and manufacturing of JADE101 and future programs, marking a significant step in its operational strategy. Additionally, the company appointed Bradford Dahms as Chief Financial Officer, effective July 14, 2025, bringing extensive financial and strategic leadership experience to support Jade’s growth and advancement of its therapies for autoimmune diseases.
The most recent analyst rating on (JBIO) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Jade Biosciences stock, see the JBIO Stock Forecast page.
Spark’s Take on JBIO Stock
According to Spark, TipRanks’ AI Analyst, JBIO is a Underperform.
Aerovate Therapeutics’ stock score reflects substantial financial challenges, including zero revenue and growing losses, which heavily weigh on the overall score. While there is positive momentum in technical analysis and significant corporate events such as the merger with Jade Biosciences, the negative valuation and financial instability are major concerns. The stock remains highly speculative with risks due to its financial performance.
To see Spark’s full report on JBIO stock, click here.
More about Jade Biosciences
Jade Biosciences is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE101, targets the cytokine APRIL for the treatment of immunoglobulin A nephropathy, with a first-in-human clinical trial expected in the second half of 2025. Jade’s pipeline also includes a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development.
Average Trading Volume: 336,115
Technical Sentiment Signal: Buy
Current Market Cap: $296.2M
For an in-depth examination of JBIO stock, go to TipRanks’ Overview page.